MedTrace Logo

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

NCT00389792 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2009-03-11

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and efficacy of an investigational antiarrhythmic drug (ATI-2042) in the treatment of atrial fibrillation in patients with a dual chamber pacemaker.

Conditions

Interventions

DRUG

ATI-2042

no intervention

DRUG

ATI-2042 200 mg

To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.

Sponsors & Collaborators

  • ARYx Therapeutics

    lead INDUSTRY

Principal Investigators

  • Michael Ezekowitz, MBChB, PhD · Main Line Health

  • Olga Bandman, MD · ARYx Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389792 on ClinicalTrials.gov